MMEA
CRSP icon

Main Management ETF Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Main Management ETF Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,009
Closed -$944K – 128
2025
Q4 		$944K Buy
18,009
+184
+1% +$11K 0.03% 104
2025
Q3 		$1.16M Sell
17,825
-1,966
-10% -$113K 0.04% 98
2025
Q2 		$963K Buy
19,791
+324
+2% +$12.5K 0.04% 90
2025
Q1 		$662K Buy
19,467
+5,939
+44% +$252K 0.03% 108
2024
Q4 		$532K Sell
13,528
-1,216
-8% -$57.4K 0.02% 137
2024
Q3 		$693K Buy
+14,744
New +$748K 0.03% 132

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Main Management ETF Advisors's CRSP Position: Q1 2026 in Review

Main Management ETF Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 18,009 shares — an estimated $944K sold.

Main Management ETF Advisors first reported a position in CRSP in Q3 2024 and held it in 6 quarters. The position peaked at $1.16M in Q3 2025. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Main Management ETF Advisors reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Main Management ETF Advisors sold 18,009 CRISPR Therapeutics shares in Q1 2026, an estimated $944K.
  • Main Management ETF Advisors first reported a position in CRISPR Therapeutics in Q3 2024 and held it in 6 quarters.
  • Main Management ETF Advisors's CRISPR Therapeutics position peaked at $1.16M in Q3 2025.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Main Management ETF Advisors's 13F filing for Q1 2026, filed 15 May 2026.